TransMedics Group, Inc. TMDX Product — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by TransMedics Group, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: TransMedics Group, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about TransMedics Group, Inc.'s product — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TransMedics Group, Inc.'s product — revenue?
- TransMedics Group, Inc. (TMDX) reported product — revenue of $107.97M in Q1 2026.
- How has TransMedics Group, Inc.'s product — revenue changed year-over-year?
- TransMedics Group, Inc.'s product — revenue increased by 22.4% year-over-year, from $88.23M to $107.97M.
- What is the long-term trend for TransMedics Group, Inc.'s product — revenue?
- Over 4 years (2021 to 2025), TransMedics Group, Inc.'s product — revenue has grown at a 86.5% compound annual growth rate (CAGR), from $30.78M to $372.4M.
- What does product — revenue mean?
- This metric represents the total gross income generated from the sale of physical goods or proprietary medical technology products within a specific business segment. It serves as a primary indicator of market adoption and commercial scaling for the company's core product offerings. Growth in this area reflects the successful expansion of the installed base and recurring utilization of the company's technology.